Idorsia Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd

Patrick Bouis

Christoph Boss

Hamed Aissaoui

Romain Siegrist

Julien Hazemann

Markus Von Raumer

The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTHreceptor modulators.

Crystalline forms

The present invention relates to azaindole acetic acid derivatives of formula (I), wherein Rand Rare as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin Dreceptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators

[object Object]

The present invention relates to azaindolle acetic acid derivatives of formula (I), wherein Rand Rare as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin Dreceptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

Growing community of inventors

Allschwil, Switzerland

Patrick Bouis